Insider buying last 90 days
No open-market insider purchases were filed for TXG in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every TXG insider filing, plotted on the chart in Gekko.Open TXG in Gekko
NASDAQ: TXG
10x Genomics (TXG) Stock Analysis & Forecast
Sep 28 close
$88.50+2.79 (+3.3%)
Gekko Brief
AI summary10x Genomics shares rose 3.3% this week amid continued attention to insider activity, with director Shehnaaz Suliman selling $464,667 in stock on September 22 under a Rule 10b5-1 trading plan, and CEO Serge Saxonov completing five sales of Class A shares the same day at weighted-average prices between $78.2284 and $82.3650. These transactions occurred as the stock traded near its 52-week high following a sustained rally. Coverage also noted comparisons with peer healthcare names and continued reference to the company's spatial platform momentum from its most recent quarter.
TXG closed at $88.50, just below its 52-week high of $89.95, and remains well above both its 50-day average of $61.26 and 200-day average of $33.26, reflecting a strong uptrend. The GekkoIndex reading of 45 places the stock in the Neutral zone. Price sits 50.4% above Gekko Fair Value of $58.86, a notable gap that stands out against the trend's strength.
Over the next 20 trading days, the next earnings report is scheduled for 5 November 2026, after the close, 37 days away and outside this window. No insider, Congress, or unusual options activity appears in the respective 90-day and 30-day windows. Seasonality has historically been a headwind from this point in the calendar, with the next 20 trading days averaging -5% over 5 years, rising in only 2 of them. Analyst consensus among 15 firms includes 6 buy and 9 hold ratings, with a consensus target of $56.60.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
10x Genomics price vs fair value
Close $88.50200-day averageGekko Fair Value $58.86
10x Genomics quick facts
- Market cap
- $11.24B
- P/E ratio
- —
- Forward P/E
- 1250
- EPS, TTM
- −$0.66
- Revenue, TTM
- $616.9M
- Profit margin
- -12.2%
- Dividend yield
- —
- Beta
- 2.08
- Volume
- 3.37M avg 2.86M
- 1-year return
- +640.6%
- Typical daily move
- ±6.2%
- Typical 20-day move
- ±13.2%
- 50-day average
- $61.26
- 200-day average
- $33.26
- Next earnings
- Nov 5 after close
- Shares outstanding
- 120.2M
10x Genomics swing-trade checklist
10x Genomics scores 2 supportive, 1 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive1 mixed2 headwinds
- Trendsupportive
Above 50 and 200-day
Close $88.50 is above the 50-day ($61.26) and 200-day ($33.26) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
45, Neutral
Reading 45 is in the Neutral zone.
See the GekkoIndex - Fair valueheadwind
50.4% above
Price is 50.4% above Gekko Fair Value (more than 5% above).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 37 days
Next report Nov 5, 2026, 37 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−5.0% on average
From this point in the calendar, the next 20 trading days averaged −5% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
10x Genomics stock chart and price history
10x Genomics closed at $88.50 on Sep 28, 2026, +640.6% over the past year, inside a 52-week range of $11.16 to $89.95.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +36.5%
- 3 months
- +138.2%
- 6 months
- +354.3%
- 1 year
- +640.6%
The full TXG chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open TXG in Gekko
Follow 10x Genomics through every session
Put TXG on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track TXG in GekkoFree for 7 days. No credit card required.
About 10x Genomics
10x Genomics builds tools that let scientists study biology at the level of individual cells and within tissue samples. Its equipment, supplies and software are used to examine gene activity, immune cell behavior, and the physical structure of DNA, giving researchers a detailed picture of how biological systems function. The company is particularly known for its Chromium and Chromium Connect instruments, which work alongside microfluidic chips, slides and reagents to support this kind of single-cell analysis.
Much of its product range centers on single-cell applications built around the Chromium platforms, covering gene expression, immune profiling, chromatin accessibility, and combined measurement of genetic and epigenetic activity across large numbers of cells at once. The company also produces a spatial gene expression solution called Visium, which maps where gene activity occurs within tissue sections and can be paired with immunofluorescence to detect proteins alongside gene expression. Customers span academic institutions, government bodies, and biopharmaceutical and biotechnology organizations, and the company's reach extends across North America, Europe, the Middle East, Africa, China and the Asia Pacific.
10x Genomics is headquartered in Pleasanton, California, and traces its founding to 2012, having operated for a time under the name 10X Technologies before adopting its current name. Its shares are listed on the NASDAQ under the ticker TXG.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- 10xgenomics.com
10x Genomics GekkoIndex: the smart money zone
10x Genomics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 45, in the Neutral zone, down 0.2 points over five sessions.
45Neutral
Down 0.2 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 88 | −0.3% | −6.1% | ||
| Accumulation | 201 | −0.2% | +2.1% | ||
| Neutral (current zone) | 340 | +2.2% | +6.9% | ||
| Distribution | 42 | −1.2% | +1.9% | ||
| Selling | 1 | Too few readings yet | |||
Average TXG share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the TXG price, zone by zone.Track TXG in Gekko
Is 10x Genomics stock overvalued? Gekko Fair Value
10x Genomics trades 50.4% above Gekko Fair Value of $58.86, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what 10x Genomics shares are worth, recalculated every trading day.
$58.86
Gekko Fair Value, Sep 26, 2026
50.4% Overvalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open TXG in Gekko
10x Genomics insider and Congress trading
No open-market insider purchases were filed for 10x Genomics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in TXG were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for TXG, plotted on the chart in Gekko.Open TXG in Gekko
Buybacks
10x Genomics has been buying back its own shares.
- Bought back, year ended Dec 31, 2017
- $80K
- As a share of market cap
- 0.00%
From company filings.
Hedge funds and billionaires quarter ended Jun 30
2of the funds Gekko tracks hold TXG.
0added2opened0trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
10x Genomics earnings: next date and track record
10x Genomics reports on Nov 5, 2026, after the close (37 days away), and beat the EPS estimate in 6 of its last 8 reports.
Next earnings report
Nov 5, 2026
Expected after the close, 37 days away
- EPS estimate
- −$0.27
- Revenue estimate
- $147.7M
6 of 8reports beat the EPS estimate
±5.8%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 6, 2026 AI summary
- What they said
- 10x Genomics reported Q2 2026 revenue of $151 million, including $1.6 million in non-recurring Takara settlement revenue. Excluding that, organic revenue was $149 million, up 3% YoY. The quarter was highlighted by strong customer reception to the new Atera spatial platform, with robust Chromium consumable volume growth and strong Xenium utilization. Atera generated significant early order flow across universities, academic medical centers, and biopharma companies spanning oncology, neurodegeneration, and other disease areas.
- Guidance
- Management did not provide explicit revenue or earnings targets in this excerpt. However, the company expressed strong confidence in Atera's commercial trajectory, citing exceptional order momentum and demand for Catalyst Research Services ahead of full commercial availability.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | −$0.14 est −$0.23 | $151.0M est $146.7M | +9.6% |
| May 7, 2026 | −$0.10 est −$0.29 | $150.8M est $146.4M | −5.0% |
| Feb 12, 2026 | −$0.13 est −$0.19 | $166.0M est $159.7M | −5.4% |
| Nov 6, 2025 | −$0.22 est −$0.07 | $149.0M est $142.5M | +13.0% |
| Aug 7, 2025 | $0.28 est −$0.35 | $172.9M est $139.5M | −2.9% |
| May 8, 2025 | −$0.36 est −$0.45 | $154.9M est $145.3M | +5.5% |
| Feb 12, 2025 | −$0.40 est −$0.29 | $165.0M est $165.0M | +1.0% |
| Oct 29, 2024 | −$0.30 est −$0.34 | $151.7M est $153.3M | +4.0% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
10x Genomics stock forecast and analyst price targets
Analysts’ average 12-month price target for 10x Genomics is $56.60, −36.0% from the last close, from 15 firms rating the stock in the last 90 days.
$56.60consensus 12-month target, −36.0% from the last close
Now $88.50Avg $56.60
Low $40High $110
Each firm’s latest rating in the last 90 days: 15 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 28 | Piper Sandler | $80 | −9.6% |
| Sep 28 | Argus Research | $110 | +24.3% |
| Sep 25 | Argus Research | $110 | +24.3% |
| Sep 9 | UBS | $68 | −23.2% |
| Sep 1 | RBC Capital | $70 | −20.9% |
+6.9%average 20-day move after past Neutral readings
−5.0%average move over the next 20 trading days in the last 5 years
±6.2%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
10x Genomics seasonality: the next 20 trading days
Over the next 20 trading days from Sep 29, 10x Genomics averaged −5.0% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −0.4% | 2 of 5 |
| Next 10 trading days | −7.1% | 2 of 5 |
| Next 15 trading days | −4.7% | 2 of 5 |
| Next 20 trading days | −5.0% | 2 of 5 |
| Next 30 trading days | +9.3% | 3 of 5 |
For scale, TXG’s typical 20-trading-day move in either direction is about 13.2%.
10x Genomics market cap and key statistics
10x Genomics’s market cap is $11.24B and revenue of $616.9M over the last twelve months.
Valuation
- Market cap
- $11.24B
- Forward P/E
- 1250
- EPS, TTM
- −$0.66
- Gekko Fair Value
- $58.86
Trading
- Volume
- 3.37M
- Avg volume, 20 days
- 2.86M
- 52-week high
- $89.95
- 52-week low
- $11.16
- Shares outstanding
- 120.2M
Financials
- Revenue, TTM
- $616.9M
- Profit margin
- -12.2%
- Return on equity
- -9.4%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 2.08
- Typical daily move
- ±6.2%
- Typical 20-day move
- ±13.2%
10x Genomics stock news this week
Coverage of 10x Genomics this week reads negative: 0 positive, 2 neutral and 4 negative headlines.
- 10x Genomics (NASDAQ:TXG) Stock: Insider Shehnaaz Suliman Sells 5,723 SharesDefense World, Sep 26
- 10x Genomics (NASDAQ:TXG) Stock: Insider Serge Saxonov Sells 25,000 SharesDefense World, Sep 26
- 10x genomics director Shehnaaz Suliman sells $464,667 in stockInvesting.com, Sep 25
- Under a trading plan, a 10x Genomics (TXG) director sells 5,723 shares in five transactions.Stock Titan, Sep 24
- 10x genomics director Shehnaaz Suliman sells $464,667 in stock By Investing.comInvesting.com Canada, Sep 24
- At $77.75 to $82.53 a share, 10x Genomics (TXG) CEO made five sales under a trading plan.Stock Titan, Sep 24
10x Genomics peers
10x Genomics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 24.4% below |
| GILDGilead Sciences | Neutral | 6.9% above |
| MRNAModerna | Neutral | 73.2% above |
| NTRANatera | Distribution | 25.1% above |
| IQVIQVIA | Neutral | 14.2% above |
| UTHRUnited Therapeutics | Accumulation | 23.6% below |
A peer links to its own page where one exists.
10x Genomics stock FAQ
What is 10x Genomics’s market cap?
10x Genomics’s market cap is $11.24B at the Sep 28, 2026 close of $88.50, with 120.2M shares outstanding.
What is the 10x Genomics stock forecast?
The consensus analyst 12-month price target for 10x Genomics is $56.60, −36.0% from the last close. Of the 15 firms that rated the stock in the last 90 days, 6 rate it a buy, 9 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is 10x Genomics stock overvalued or undervalued?
On Gekko’s estimate 10x Genomics is overvalued: the Sep 28, 2026 close of $88.50 is 50.4% above Gekko Fair Value of $58.86. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does 10x Genomics report earnings next?
10x Genomics is expected to report on Nov 5, 2026, after the market closes (37 days away). Analysts expect earnings of −$0.27 per share on revenue of $147.7M. 10x Genomics beat the earnings estimate in 6 of its last 8 reports, moving 5.8% on average across the report.
What is 10x Genomics’s 52-week high and low?
10x Genomics’s 52-week high is $89.95 and its 52-week low is $11.16; it closed at $88.50 on Sep 28, 2026, +640.6% over the past year. Over the last five years the shares peaked at $187.85 on Nov 4, 2021.
Is 10x Genomics stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and earnings risk), 1 as mixed (gekkoindex) and 2 as headwinds (fair value and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See 10x Genomics the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.